• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by American Well Corporation (Amendment)

    2/12/24 4:40:13 PM ET
    $AMWL
    Business Services
    Consumer Discretionary
    Get the next $AMWL alert in real time by email
    SC 13G/A 1 dp206629_sc13ga-3.htm FORM SC 13G/A
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 3)*

     

    American Well Corporation
    (Name of Issuer)
     
    Class A Common Stock, par value $0.01 par value per share
    (Title of Class of Securities)
     
    03044L105
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☐ Rule 13d-1(c)

     

    ☒ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 03044L105SCHEDULE 13G
    1

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Ido Schoenberg

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)

    (b)

     

    ☒

    ☐

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Israel

    NUMBER OF
    SHARES
    BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
    5 SOLE VOTING POWER
      NONE
    6 SHARED VOTING POWER
      16,551,623(1)
    7 SOLE DISPOSITIVE POWER
      16,551,623
    8 SHARED DISPOSITIVE POWER
      NONE
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    16,551,623(1)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.1%(2)(3)

    12

    TYPE OF REPORTING PERSON

     

    IN

    (1) Consists of (i) 1,295,149 shares of Class A Common Stock, (ii) 20,311 shares of Class A Common Stock to be issued pursuant to vesting of restricted stock units within 60 days of December 31, 2023, (iii) 13,471,279 shares of Class B Common Stock and (iv) 1,764,884 shares of Class B Common Stock underlying options that are currently exercisable. Each share of Class B Common Stock is convertible into one share of the Issuer’s Class A Common Stock at any time at the option of the holder thereof. Dr. Ido Schoenberg and Dr. Roy Schoenberg are parties to a voting agreement whereby each has agreed to vote their shares together as a group. Accordingly, each of Dr. Ido Schoenberg and Dr. Roy Schoenberg may be deemed to beneficially own each other’s stock with shared voting power, currently consisting in the aggregate of 3,379,945 shares of Class A Common Stock and 30,920,165 shares of Class B Common Stock.

     

    (2) Based on the quotient obtained by dividing (a) the aggregate number of Class A Common Stock and Class B Common Stock, together, beneficially owned by the Reporting Person as set forth in Row 9 by (b) the sum of (i) 255,542,545 shares of Class A Common Stock outstanding as of December 31, 2023 and (ii) the aggregate number of shares of Class B Common Stock beneficially owned by the Reporting Person. The aggregate number of shares of Class B Common Stock beneficially owned by the Reporting Person as set forth in clauses “(a)” and “(b)” of this footnote are treated as converted into shares of Class A Common Stock solely for the purpose of computing the percentage ownership of the Reporting Person.

     

    CUSIP No. 03044L105SCHEDULE 13G

     

    (3) Each share of Class A Common Stock is entitled to one vote, and shares of Class B Common Stock will collectively be entitled to a number of votes equal to the product of (x) 1.0408163 and (y) the total number of votes that would be cast at such time by the holders of the Class A and Class C Common Stock and any other preferred stock entitled to vote under the Issuer’s certificate of incorporation at such time (resulting in the Class B Common Stock collectively holding 51% of the total outstanding voting power). Accordingly, each of Dr. Ido Schoenberg and Dr. Roy Schoenberg each own 25.5% of the total outstanding voting power, and based on their voting agreement, their interests collectively represent 51% of the aggregate voting power of the Issuer’s issued and outstanding share capital.

    3 

    CUSIP No. 03044L105SCHEDULE 13G


     

    1

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Roy Schoenberg

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)

    (b)

     

    ☒

    ☐

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
    5 SOLE VOTING POWER
      NONE
    6 SHARED VOTING POWER
      17,748,487(1)
    7 SOLE DISPOSITIVE POWER
      17,748,487
    8 SHARED DISPOSITIVE POWER
      NONE
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    17,748,487(1)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.5%(2)(3)

    12

    TYPE OF REPORTING PERSON

     

    IN

     

    (1) Consists of (i) 2,044,174 shares of Class A Common Stock, (ii) 20,311 shares of Class A Common Stock to be issued pursuant to vesting of restricted stock units within 60 days of December 31, 2023, (iii) 13,919,118 shares of Class B Common Stock and (iv) 1,764,884 shares of Class B Common Stock underlying options that are currently exercisable. Each share of Class B Common Stock is convertible into one share of the Issuer’s Class A Common Stock at any time at the option of the holder thereof. Dr. Ido Schoenberg and Dr. Roy Schoenberg are parties to a voting agreement whereby each has agreed to vote their shares together as a group. Accordingly, each of Dr. Ido Schoenberg and Dr. Roy Schoenberg may be deemed to beneficially own each other’s stock with shared voting power, currently consisting in the aggregate of 3,379,945 shares of Class A Common Stock and 30,920,165 shares of Class B Common Stock.

     

    (2) Based on the quotient obtained by dividing (a) the aggregate number of Class A Common Stock and Class B Common Stock, together, beneficially owned by the Reporting Person as set forth in Row 9 by (b) the sum of (i) 255,542,545 shares of Class A Common Stock outstanding as of December 31, 2023 and (ii) the aggregate number of shares of Class B Common Stock beneficially owned by the Reporting Person. The aggregate number of shares of Class B Common Stock beneficially owned by the Reporting Person as set forth in clauses “(a)” and “(b)” of this footnote are treated as converted into shares of Class A Common Stock solely for the purpose of computing the percentage ownership of the Reporting Person.

     

    4 

    CUSIP No. 03044L105SCHEDULE 13G

    (3) Each share of Class A Common Stock is entitled to one vote, and shares of Class B Common Stock will collectively be entitled to a number of votes equal to the product of (x) 1.0408163 and (y) the total number of votes that would be cast at such time by the holders of the Class A and Class C Common Stock and any other preferred stock entitled to vote under the Issuer’s certificate of incorporation at such time (resulting in the Class B Common Stock collectively holding 51% of the total outstanding voting power). Accordingly, each of Dr. Ido Schoenberg and Dr. Roy Schoenberg each own 25.5% of the total outstanding voting power, and based on their voting agreement, their interests collectively represent 51% of the aggregate voting power of the Issuer’s issued and outstanding share capital.

     

    5 

    CUSIP No. 03044L105SCHEDULE 13G

    Item 1.   (a) NAME OF ISSUER

     

    American Well Corporation (the “Company”)

     

    (b)  ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

     

    75 State Street

     

    26th Floor

     

    Boston, MA 02109

     

    Item 2. (a) NAMES OF PERSONS FILING

     

    This Statement is being filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

     

    (i)Ido Schoenberg

     

    (ii)Roy Schoenberg

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

     

    (b)  ADDRESS OF PRINCIPAL BUSINESS OFFICE

     

    The principal addresses of the Reporting Persons are as follows:

     

    75 State Street

    26th Floor 

    Boston, MA 02109

     

    (c)  CITIZENSHIP

     

    (i)Ido Schoenberg – Israel

     

    (ii)Roy Schoenberg – United States

     

    (d)  TITLE OF CLASS OF SECURITIES

     

    Class A common stock, par value $0.01 per share (the “Shares”)

     

    (e)  CUSIP NUMBER

     

    03044L105

     

    6 

    CUSIP No. 03044L105SCHEDULE 13G

     

    Item 3.IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS:

     

    Not applicable.

     

    Item 4.OWNERSHIP.

     

    (a)Amount Beneficially Owned as of December 31, 2023:

     

    (i)  Ido Schoenberg: 16,551,623 Shares (1)

     

    (ii)  Roy Schoenberg: 17,748,487 Shares (2)

     

    (b)Percentage Owned:

     

    (i)  Ido Schoenberg: 6.1% (3)(4)

     

    (ii)  Roy Schoenberg: 6.5% (3)(4)

     

    (c)Number of Shares as to Which Such Person Has:

     

    (i) sole power to vote or direct the vote of

     

    (A)  Ido Schoenberg: 0

     

    (B)  Roy Schoenberg: 0

     

    (ii) shared power to vote or direct the vote of

     

    (A)  Ido Schoenberg: 16,551,623 (1)

     

    (B)  Roy Schoenberg: 17,748,487 (2)

     

    (iii) sole power to dispose or to direct the disposition of

     

    (A)  Ido Schoenberg: 16,551,623

     

    (B)  Roy Schoenberg: 17,748,487

     

    (iv) shared power to dispose or to direct the disposition of

     

    (A)  Ido Schoenberg: 0

     

    (B)  Roy Schoenberg: 0

     

    Notes:

     

    (1)Consists of (i) 1,295,149 shares of Class A Common Stock, (ii) 20,311 shares of Class A Common Stock to be issued pursuant to vesting of restricted stock units within 60 days of December 31, 2023, (iii) 13,471,279 shares of Class B Common Stock and (iv) 1,764,884 shares of Class B Common Stock underlying options that are currently exercisable. Each share of Class B Common Stock is convertible into one share of the Issuer’s Class A Common Stock at any time at the option of the holder thereof. Dr. Ido Schoenberg and Dr. Roy Schoenberg are parties to a voting agreement whereby each has agreed to vote their shares together as a group. Accordingly, each of Dr. Ido Schoenberg and Dr. Roy Schoenberg may be deemed to beneficially own each other’s stock with shared voting power, currently consisting in the aggregate of 3,379,945 shares of Class A Common Stock and 30,920,165 shares of Class B Common Stock.

     

    (2)Consists of (i) 2,044,174 shares of Class A Common Stock, (ii) 20,311 shares of Class A Common Stock to be issued pursuant to vesting of restricted stock units within 60 days of December 31, 2023,

     

    7 

    CUSIP No. 03044L105SCHEDULE 13G

    (iii) 13,919,118 shares of Class B Common Stock and (iv) 1,764,884 shares of Class B Common Stock underlying options that are currently exercisable. Each share of Class B Common Stock is convertible into one share of the Issuer’s Class A Common Stock at any time at the option of the holder thereof. Dr. Ido Schoenberg and Dr. Roy Schoenberg are parties to a voting agreement whereby each has agreed to vote their shares together as a group. Accordingly, each of Dr. Ido Schoenberg and Dr. Roy Schoenberg may be deemed to beneficially own each other’s stock with shared voting power, currently consisting in the aggregate of 3,379,945 shares of Class A Common Stock and 30,920,165 shares of Class B Common Stock.

     

    (3)Based on the quotient obtained by dividing (a) the aggregate number of Class A Common Stock and Class B Common Stock, together, beneficially owned by the Reporting Person as set forth in Row 9 by (b) the sum of (i) 255,542,545 shares of Class A Common Stock outstanding as of December 31, 2023, and (ii) the aggregate number of shares of Class B Common Stock beneficially owned by the Reporting Person. The aggregate number of shares of Class B Common Stock beneficially owned by the Reporting Person as set forth in clauses “(a)” and “(b)” of this footnote are treated as converted into shares of Class A Common Stock solely for the purpose of computing the percentage ownership of the Reporting Person.

     

    (4)Each share of Class A Common Stock is entitled to one vote, and shares of Class B Common Stock will collectively be entitled to a number of votes equal to the product of (x) 1.0408163 and (y) the total number of votes that would be cast at such time by the holders of the Class A and Class C Common Stock and any other preferred stock entitled to vote under the Issuer’s certificate of incorporation at such time (resulting in the Class B Common Stock collectively holding 51% of the total outstanding voting power). Accordingly, each of Dr. Ido Schoenberg and Dr. Roy Schoenberg each own 25.5% of the total outstanding voting power, and based on their voting agreement, their interests collectively represent 51% of the aggregate voting power of the Issuer’s issued and outstanding share capital.

     

    Item 5.OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    Not applicable.

     

    Item 6.OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

    Not applicable.

     

    Item 7.IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

     

    Not applicable.

     

    Item 8.IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

     

    See Item 4, which states the identity of the members of the group filing this Schedule 13G.

     

    Item 9.NOTICE OF DISSOLUTION OF GROUP

     

    Not applicable.

     

    Item 10.CERTIFICATION

     

    Not applicable.

     

    8 

    CUSIP No. 03044L105SCHEDULE 13G

    Exhibit Index

     

    Exhibit 99.1. Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

     

    9 

    CUSIP No. 03044L105SCHEDULE 13G

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated as of February 12, 2024

     

     

    IDO SCHOENBERG

     

      By: /s/ Ido Schoenberg
     

     

     

    ROY SCHOENBERG

     

      By: /s/ Roy Schoenberg

     

    10 

    Get the next $AMWL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMWL

    DatePrice TargetRatingAnalyst
    1/13/2025$15.00Equal Weight → Overweight
    Wells Fargo
    8/3/2023$5.00 → $2.50Overweight → Equal-Weight
    Morgan Stanley
    3/23/2023$5.00 → $2.50Outperform → Market Perform
    TD Cowen
    2/27/2023$5.00 → $3.50Overweight → Neutral
    Piper Sandler
    1/4/2023$4.20Neutral → Buy
    BofA Securities
    9/7/2022$5.00Hold
    Truist
    4/14/2022$6.00Buy
    Guggenheim
    4/1/2022$5.00Neutral
    Credit Suisse
    More analyst ratings

    $AMWL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amwell makes grant to new employee under inducement plan

      BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading technology-enabled care platform provider, announced that on May 6, Amwell made a grant of RSUs of 3,451 shares of its Class A common stock to one new employee. The grant was offered as material inducement to the employee's employment with Amwell. The RSUs will vest as follows, subject to the employee's continued employment through the applicable vesting date: 25% of the RSUs will vest upon the first anniversary of the grant date ("Initial Vesting Date"), and the remaining 75% of the RSUs will vest in equal pro rata increments every three months thereafter (beginning on the first calendar day of the month following the

      5/6/25 4:05:00 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • Amwell® Announces Results for First Quarter 2025

      BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL) a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the first quarter ended March 31. Visit Amwell's investor relations website at investors.amwell.com to view the first quarter 2025 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, May 1. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/9tn5fcf6. A replay of the call will be available via webcast shortly after the completion of the call, at investors.amwell.com. About Amwell Amwell offers payers and

      5/1/25 4:05:00 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • Amwell® to participate in upcoming investor conferences

      BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will participate in the following upcoming investor conferences:   On May 8, Mark Hirschhorn, chief financial officer and chief operating officer, will participate in one-on-one meetings at the Needham & Co. Virtual Technology and Services Conference held virtually. On June 24, Hirschhorn will participate in the Truist Securities Healthcare Disruptors & Digital Health Conference in New York City.    About Amwell Amwell offers payers and health systems a single, comprehensive, technology-enabled care platform. We use technolo

      4/24/25 7:30:00 AM ET
      $AMWL
      Business Services
      Consumer Discretionary

    $AMWL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amwell upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Amwell from Equal Weight to Overweight and set a new price target of $15.00

      1/13/25 7:29:38 AM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • Amwell downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Amwell from Overweight to Equal-Weight and set a new price target of $2.50 from $5.00 previously

      8/3/23 6:19:10 AM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • Amwell downgraded by TD Cowen with a new price target

      TD Cowen downgraded Amwell from Outperform to Market Perform and set a new price target of $2.50 from $5.00 previously

      3/23/23 7:15:52 AM ET
      $AMWL
      Business Services
      Consumer Discretionary

    $AMWL
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by American Well Corporation

      SCHEDULE 13G/A - American Well Corp (0001393584) (Subject)

      5/15/25 4:21:34 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • SEC Form 10-Q filed by American Well Corporation

      10-Q - American Well Corp (0001393584) (Filer)

      5/1/25 4:13:22 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • American Well Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - American Well Corp (0001393584) (Filer)

      5/1/25 4:10:12 PM ET
      $AMWL
      Business Services
      Consumer Discretionary

    $AMWL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Mcneice Paul Francis sold $747 worth of shares (113 units at $6.61), decreasing direct ownership by 0.78% to 14,366 units (SEC Form 4)

      4 - American Well Corp (0001393584) (Issuer)

      6/4/25 5:01:52 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • President, International Gotlib Phyllis sold $31,628 worth of shares (4,782 units at $6.61), decreasing direct ownership by 3% to 141,849 units (SEC Form 4)

      4 - American Well Corp (0001393584) (Issuer)

      6/4/25 5:01:14 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • President, International Gotlib Phyllis sold $2,155 worth of shares (299 units at $7.21), decreasing direct ownership by 0.20% to 146,631 units (SEC Form 4)

      4 - American Well Corp (0001393584) (Issuer)

      5/5/25 4:31:36 PM ET
      $AMWL
      Business Services
      Consumer Discretionary

    $AMWL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by American Well Corporation

      SC 13G/A - American Well Corp (0001393584) (Subject)

      11/12/24 4:43:25 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G filed by American Well Corporation

      SC 13G - American Well Corp (0001393584) (Subject)

      11/6/24 4:14:27 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G filed by American Well Corporation

      SC 13G - American Well Corp (0001393584) (Subject)

      11/4/24 11:53:44 AM ET
      $AMWL
      Business Services
      Consumer Discretionary

    $AMWL
    Financials

    Live finance-specific insights

    See more
    • Amwell® Announces Results for First Quarter 2025

      BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL) a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the first quarter ended March 31. Visit Amwell's investor relations website at investors.amwell.com to view the first quarter 2025 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, May 1. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/9tn5fcf6. A replay of the call will be available via webcast shortly after the completion of the call, at investors.amwell.com. About Amwell Amwell offers payers and

      5/1/25 4:05:00 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • Amwell® to report first quarter 2025 operating results

      BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, will report first quarter 2025 operating results after stock market trading hours on Thursday, May 1 2025. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at investors.amwell.com for approximately 90 days. About Amwell  Amwell offers payers and

      4/17/25 7:05:00 AM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • Amwell® Announces Results for Fourth Quarter and Full Year 2024

      BOSTON, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the fourth quarter and full year ended Dec. 31, 2024. Visit Amwell's investor relations website at investors.amwell.com to view the fourth quarter and full year 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Feb. 12. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/zsp4abpw. A replay of the call will be available via webcast shortly after the completion of the call, at investors.amwell.com. Abo

      2/12/25 4:05:00 PM ET
      $AMWL
      Business Services
      Consumer Discretionary

    $AMWL
    Leadership Updates

    Live Leadership Updates

    See more
    • Amwell announces new chief financial officer

      BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, today announced Mark Hirschhorn will become Amwell Chief Financial Officer (CFO) effective Oct. 21, succeeding Robert "Bob" Shepardson, who has been in the role since 2021. Hirschhorn will oversee Amwell's financial operations, enterprisewide optimization and capital allocation activities, and will play a meaningful leadership role in guiding the company's strategy to support its long-term growth objectives and enhance shareholder value.   Hirschhorn is a healthcare technology industry leader, with over three decades of experience in financial and strategic operations, having served in senior executiv

      10/15/24 4:30:00 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • Amwell Announces Appointment of Ricky Goldwasser to its Board of Directors

      Boston, June 17, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in hybrid care enablement, today announces the appointment of Ricky Goldwasser to the company's Board of Directors, effective June 13. "Ricky brings to our board a deep financial background that makes her an invaluable addition as we focus on Amwell's path to profitability. Ricky's strong voice coupled with her impressive track record will help guide Amwell as we strive for greater efficiencies, optimized cash flow and profitable growth, while remaining committed to enabling our clients to achieve their goals. We are pleased to welcome Ricky to the team," said Ido Schoenberg, M.D., CEO and chairman, Amwell. Ms. Gol

      6/17/24 8:05:00 AM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

      ALACHUA, Fla. and TAMPA, Fla., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce today the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December 20, 2023. Weiler, a senior executive with 20+ years of experience and proven track record in driving strategic commercial initiatives, will serve on the Board's Governance, Nominating and Sustainability Committee, and the Quality, Compliance, and Portfolio Management Committee. "I am happy to welcome Kathy to the Board as Axogen is approaching an exciting inflection point in its journ

      12/26/23 4:15:00 PM ET
      $AMWL
      $AXGN
      Business Services
      Consumer Discretionary
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care